// App-Quantinova.ai

1300 : Effectiveness of icatibant to control symptoms of HAE attacks in real‐world clinical practice

Researchers

Presenter

  • Caballero T

Principal Investigators

  • Maurer M

  • Longhurst HJ

  • Bouillet L

  • Grumach AS

  • Botha J

  • Andresen I

  • Aberer W

Medical Centers

  • Department of Allergy, Hospital La Paz Institute for Health Research (IdiPaz), Biomedical Research Network on Rare Diseases (CIBERER, U754), Madrid, Spain

  • Dermatological Allergology, Allergie‐Centrum‐Charité, Department of Dermatology and Allergy, Charité Universitätsmedizin, Berlin, Germany

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • University College London Hospitals NHS Trust, London, United Kingdom

  • National Reference Centre for Angioedema, Internal Medicine Department, Grenoble University, Grenoble, France

  • Clinical Immunology, Medical School, University Center Health ABC, Santo Andre, Brazil

  • Shire, a Takeda Company, Zug, Switzerland

  • Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria

Locations

  • Spain

  • Germany

  • United Kingdom

  • France

  • Brazil

  • Switzerland

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Icatibant

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01034969

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved